Novo Nordisk (NVO) Earns Sell Rating As Stock Crumbles Nearly 70% From Its Peak
Novo Nordisk (NVO) has been downgraded to sell by analysts as its stock continues to suffer one of the steepest declines seen among major pharmaceutical companies in recent years. The Danish drugmaker’s market capitalization has fallen nearly 69% since hitting an all-time high of $635.7 billion in June 2024, wiping out hundreds of billions in…